Paychex PAYX
Industrials · Staffing & Employment Services · Synthos Deep Dive · 2026-07-03
The Overview
Paychex does payroll and HR paperwork for small and mid-sized businesses — it makes sure workers get paid, taxes get filed, and benefits get handled. It is boring, extremely profitable, and pays a big dividend (about 4.2% a year in cash, roughly double what a typical big stock pays).
Is the stock cheap or expensive? Fairly priced, leaning slightly rich. You pay about $22 for every $1 of yearly profit — not a bargain, not crazy — but the company is only growing profits in the low teens per year, and a lot of that came from buying a competitor (Paycor) rather than growing on its own. The stock has also fallen about 28% over the past year while the market rose, which tells you investors have cooled on it.
Our verdict is Watch — a good company, but there's no obvious reason to rush in today, and no expert we track is banging the table for it.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe). Steady cash, low stock-price swings, and a fat dividend cushion losses — but it already fell a lot, so it's not bulletproof.
- Growth Quality 5/10 (middle). Wonderfully profitable, but growing slowly. Quality high, speed low.
- Exponential Potential 2/10 (low). This is a mature "get paid to wait" income stock, not a rocket ship. Don't expect it to double.
The one big worry: cheaper, AI-driven, do-it-yourself payroll software could slowly steal small-business customers, and small businesses are exactly who suffers most in a recession.
Putting a number on it: our fair-value estimate is $108 against a current price of $127.04 — a premium price for a business we still like.
Our summary metrics
Low beta 0.83, net-debt/EBITDA 1.15x, 4.2% yield cushion the downside, but the stock is in a 28% drawdown and PEG ~2.9x is rich for the growth.
High-40s EBITDA margin and 45% ROE are elite, but mid-single-digit organic revenue and low-teens forward EPS CAGR are pedestrian.
Mature payroll compounder, decelerating post-Paycor, tiny room-to-run — this is an income name, not a multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature payroll compounder, decelerating post-Paycor, tiny room-to-run — this is an income name, not a multibagger.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $103.6 (high $110 / low $98; 5 Buy · 19 Hold · 6 Sell → Hold) — context, not our anchor |
| Valuation | 21.7× trailing EPS · 17.8× FY27E · 16.6× FY28E · 15.6× FY29E · EV/S 6.4× · EV/EBITDA 13.8× · PEG ~2.9× |
| Technicals | Downtrend/repair — $106, −28% off 52-wk high, ~at 200-DMA, above 50-DMA, RSI 64, −28% 12-mo (SPY +21%, QQQ +30%) |
| Conviction | Low — 0 expert voices, 0 KB claims. Verdict rests on fundamentals and quant only |
| Position sizing | Income/defensive satellite only, ~1–3% if held for the 4.2% yield; not a conviction buy today |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for PAYX — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $127.04, 12% above the 50-day average ($114), 23% above the 200-day average ($104) — an uptrend. 9% below the 52-week high of $139, 48% above the 52-week low of $86.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $127.04 is currently inside the band (band $116–$128).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 66.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.01, negative momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = PAYX · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Paychex, Inc. (Nasdaq: PAYX) is a Rochester, NY–based provider of human capital management (HCM) solutions — payroll processing, payroll-tax administration, HR outsourcing, retirement/benefits administration, insurance, and PEO (professional employer organization) services — sold overwhelmingly to small and mid-sized businesses (SMBs) in the US, with smaller footprints in Europe and India. Founded 1971, IPO 1983, ~16,500 employees, CEO John Gibson Jr. Fiscal year ends May 31. In FY25 Paychex closed its ~$3.3B acquisition of Paycor, a cloud HCM platform, which is the dominant reason FY26 revenue jumped ~17%.
Revenue mix (FY2025 product segmentation, from filings):
- Management Solutions $4.067B (75%) — core payroll, HR software, retirement/benefits admin.
- PEO and Insurance Solutions $1.343B (25%) — co-employment PEO, workers' comp and health insurance.
- (Note: the segmentation above predates the full Paycor consolidation; FY26 total revenue was $6.512B. FMP provides no geographic segmentation for PAYX — the business is overwhelmingly US.)
An underappreciated economic driver: Paychex holds client payroll and tax funds in float and earns interest on it, so a chunk of profitability is tied to short-term rates — a tailwind when rates are high, a headwind as they fall.
2. The expert thesis (traceability)
There is no expert coverage of PAYX in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top array is empty in the claims file. No net-bullish or cautionary voice has been distilled for this name.
Per the House Standard, conviction cannot be fabricated: with zero traceable claim_ids, this verdict is entirely fundamentals- and quant-driven, not conviction-driven. That absence is itself informative — Paychex is a mature, well-understood dividend compounder that the high-alpha voices Synthos tracks (who skew toward secular exponentials and next-generation platforms) simply do not spend their time on. The Street's own posture (a Hold consensus: 5 Buy, 19 Hold, 6 Sell) is consistent with that quiet.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Moderate-Low | Beta 0.83, net-debt/EBITDA 1.15×, 4.2% yield and a 46% EBITDA margin cushion the downside; offsetting it, PEG ~2.9× is rich, the stock is already in a 28% drawdown, and SMB exposure is cyclical. |
| Growth Quality | 5 · Average | Elite unit economics (74% gross, 46% EBITDA, 45% ROE, 20% ROIC) but mid-single-digit organic revenue and low-teens forward EPS CAGR — a high-quality business growing slowly. |
| Exponential Potential | 2 · Low | Mature category, decelerating post-Paycor, $38B cap in a well-penetrated SMB payroll market — an income compounder, not a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Paycor cross-sell and float income beat; FY28E EPS pushes to ~$6.75 (vs $6.41 cons); a re-rate back toward the historical ~20× as growth reaccelerates and rates stay supportive. | ~$135 (+27%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $5.97, FY28E $6.41; a durable but slow HCM compounder holds a ~17–18× forward multiple. | ~$108 (+2%) |
| Bear | SMB softness + falling short rates compress float income; integration disappoints; FY27E EPS slips toward ~$5.60 and the multiple de-rates to ~14–15× as the growth story stays stalled. | ~$82 (−23%) |
Synthos fair value = the base case, ~$108 (+2%), with the full $82–$135 span as the honest range. Our anchor sits essentially on top of the Street's $103.6 consensus (high $110 / low $98) — when a name has no expert edge and consensus is a genuine Hold, we don't manufacture a differentiated view. This is a tracked call; the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). PAYX is a mature compounder with essentially no exponential characteristics:
- Forward growth: revenue FY26 $6.51B → FY29E $7.61B ≈ 5% CAGR; EPS FY26 $4.90 → FY29E $6.83 ≈ 12% CAGR. Respectable, not exponential.
- Acceleration (the 2nd derivative) is negative once you strip the deal: the FY26 revenue jump (+17%) and the FY27E EPS jump (+22% to $5.97) are Paycor-acquisition artifacts — FY26 net income carried elevated integration amortization (D&A doubled to $443M) that unwinds. Organic growth reverts to mid-single-digit revenue (FY27→FY29E revenue growth decelerates 5.5% → 5.5% → 3.9%) and low-teens EPS. The inflection is behind it, not ahead.
- Room to run: the US SMB payroll/HCM market is large but mature and well-penetrated, and Paychex is already the #2 player. At $38B in a saturated category, there is no realistic path to a multibagger from share gains alone.
- Reinvestment runway: the company returns most of its cash (90% dividend payout ratio) rather than reinvesting for hyper-growth — the opposite of an exponential's profile.
Exponential Potential: Low (2/10). Own PAYX for the 4.2% yield plus low-teens total return, never for a fast multibagger. A small, accelerating name with these margins might score 8; a saturated $38B utility past its deal-driven bump scores a 2.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY26 $6.512B, +16.9% (FY25 $5.572B +5.6%; FY24 $5.278B +5.4%). The FY26 jump is Paycor-driven; underlying organic growth is mid-single-digit.
- Quarterly trajectory: the FY26 quarters (fiscal year ended 2026-05-31) ran $1.540B (Q1) → $1.558B (Q2) → $1.809B (Q3, seasonal peak) → $1.605B (Q4). Q4'26 (2026-06-24 report) EPS $1.18 beat the $1.31 consensus on an adjusted basis; reported dil EPS $1.17.
- Margins (elite): gross 74.3% TTM, EBITDA 46.2% TTM, operating ~38.6%, net 27.0% TTM. FY26 net margin 27.0% vs FY25 29.7% — the dip is deal amortization and higher interest expense from acquisition debt, not operating deterioration.
- Earnings: net income $1.760B FY26 (+6.2% over FY25 $1.657B); EPS $4.90 (dil $4.89) vs $4.60. Interest expense jumped to $269.5M (from $105M) on the Paycor debt.
- Cash flow: operating CF $2.557B FY26, capex −$235M, FCF ~$2.322B (36% FCF margin) — a cash machine. FCF comfortably covered the $1.59B of dividends and $611M of buybacks.
- Balance sheet: post-Paycor, total debt $4.61B, net debt $3.47B, net-debt/EBITDA ~1.15× — investment-grade and easily serviceable against ~$2.95B EBITDA. Goodwill/intangibles ballooned to $6.2B from the deal (38% of assets). ROE 45%, ROIC 20%.
6. Valuation — priced in or room?
PAYX is fairly-to-fully valued, not cheap. Trailing 21.7× EPS, 6.4× EV/S, 13.8× EV/EBITDA, and a PEG of ~2.9× — you're paying a premium-quality multiple for pedestrian growth. The forward multiple compresses only modestly as EPS grows: 17.8× FY27E → 16.6× FY28E → 15.6× FY29E. That is below the ~25×+ peaks PAYX has commanded in past cycles, so the 28% drawdown has taken some froth out — but it is not a value entry, and the growth doesn't justify a re-rate on its own. The 4.2% dividend yield (90% payout) is the real support: at these levels the stock is priced to deliver roughly yield + EPS growth ≈ low-teens total return if estimates hold. FMP's letter rating is B+ (overall score 3/5), dinged specifically on price-to-earnings (2/5) and price-to-book (1/5) — i.e. quality is high, cheapness is not. Street targets (context): consensus $103.6, high $110, low $98 — a tight band that itself signals "fairly valued, low disagreement." Our $108 base sits inside it.
7. Technicals (from the tech block)
- Trend: repair, not yet uptrend. $106.35 sits above the 50-DMA ($96.15) but roughly at the 200-DMA ($105.13) — reclaiming the 200-day is constructive but unconfirmed. MACD +1.44 (mildly positive).
- Location: −28.1% off the 52-week high ($147.99), +24.3% off the 52-week low ($85.57). Max drawdown from peak −33.4% — this has been a meaningful correction, not a scratch.
- Momentum: RSI(14) 64 — firm but not overbought (<70); the recent bounce (+3.5% on the print day, +17% over 3 months) has legs but isn't stretched.
- Relative strength (the tell, and it's negative): PAYX −27.9% over 12 months vs SPY +20.6% and QQQ +30.3% — a ~48–58 point relative-performance gap. Even the 6-month (−6.2% vs SPY +8.4%) trails. Only the last 3 months (+17.0% vs SPY +13.7%) show relative repair.
- Read: the chart is early-stage recovery off a deep drawdown — the stock is climbing back to its 200-DMA after badly lagging. That's consistent with a Watch: wait for a decisive 200-DMA reclaim and relief on the growth/rate story before treating the bounce as a trend.
8. Moat & competitive position
Paychex's moat is real but narrow and slow-eroding: (1) high switching costs — once payroll and tax filing run on your system, ripping them out is painful, driving sticky retention; (2) scale and compliance depth — multi-state tax and regulatory complexity is a barrier to new entrants; (3) float economics — earning interest on client tax/payroll funds is a structural profit source larger peers share. Against that: the moat is under secular pressure from lower-cost, self-serve, AI-assisted payroll (Gusto, Rippling, Deel, and Intuit/QuickBooks Payroll downmarket; Workday/ADP upmarket). The Paycor deal was partly a defensive move to modernize the cloud-HCM stack.
Peer set (FMP-supplied Industrials comps, market cap): AMETEK $53.8B, W.W. Grainger $63.4B, HEICO $50.4B, Rockwell Automation $52.5B, Roper $36.8B, Delta $60.9B, Ferguson $44.7B, Ferrovial $48.8B, Otis $28.1B, Waste Connections $42.9B. Caveat: these are broad Industrials names, not payroll/HCM pure-plays — the true competitive comp is ADP (not in this list), the larger direct rival. Read the peer set as a market-cap cohort, not a business comp.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-return-first. FY26 returned $1.59B in dividends + $611M buybacks ≈ $2.2B, essentially all of FCF, at a ~90% dividend payout ratio and a 4.2% yield. This is an income-compounder allocation policy — appropriate for a mature cash cow, but it leaves little dry powder and signals limited high-return reinvestment runway. The Paycor acquisition (~$3.3B, debt-funded) was the one large capital deployment, lifting leverage from net-cash to ~1.15× net-debt/EBITDA.
- Insider activity: the sampled window (May–Jul 2026) shows routine, small transactions — mostly F-InKind tax withholding on vesting (officers Ante, Bergstrom), a director option-exercise-and-partial-sale (Tucci), and a gift by 10% owner Golisano. No cluster of large discretionary open-market selling — nothing alarming, nothing bullish.
- Guidance: management's forward outlook (FY27 revenue and EPS ranges, Paycor synergy targets) is issued on the earnings calls; Synthos does not carry a distilled
PAYX_mgmtguidance claim in the KB for this name. Forward figures below rely on FMP analyst consensus, labeled as estimates.
10. Catalysts & what to watch
- Next earnings: 2026-09-29 (Q1'27; Street EPS $1.33, revenue ~$1.63B). Watch organic (ex-Paycor) revenue growth and Paycor synergy realization.
- Float / interest income: the path of short-term rates directly moves interest-on-funds-held; a Fed easing cycle is a headwind to watch.
- SMB health: small-business hiring, checks-per-client, and client-count trends are the leading indicators of organic growth (and the first casualty in a slowdown).
- Paycor integration: cross-sell traction and whether deal amortization/interest drag rolls off as guided — the key to the FY27 EPS step-up.
- Dividend: any raise (or a payout ratio pushing uncomfortably above 90%) is a signal on management's growth confidence.
Thesis tripwires (what would change the call): two consecutive quarters of organic revenue deceleration below ~4%; net-margin compression that isn't just deal amortization; a dividend payout ratio breaching ~100% of FCF; or client-count attrition signaling AI/self-serve share loss.
11. Key risks
- Secular (structural, #1): AI-driven and self-serve payroll (Gusto, Rippling, Deel, Intuit) chipping at the SMB base — a slow but persistent threat to the core moat.
- Cyclicality: SMB customers are recession-sensitive; a downturn hits client counts, checks-per-client, and PEO/insurance attach rates simultaneously.
- Rate sensitivity: falling short-term rates compress the float/interest-on-funds income that pads margins.
- Valuation / no-catalyst: PEG ~2.9× and a full multiple with mid-single-digit organic growth leave little room for a positive surprise to re-rate the stock; the 28% drawdown shows the downside when growth disappoints.
- Integration: a $3.3B, debt-funded Paycor deal that must deliver synergies while leverage sits at ~1.15× — execution risk on the one big bet.
- Conviction gap: zero expert coverage — no independent high-alpha voice is validating a bull case, so the entire thesis rests on quant and fundamentals.
12. Verdict, position sizing & monitoring
Watch. Paychex is a genuinely high-quality business — 46% EBITDA margins, 45% ROE, a fortress recurring-revenue model, and a well-covered 4.2% dividend — but three things keep it off the buy list today: (1) the valuation is full (PEG ~2.9×, 17–18× forward) for mid-single-digit organic growth; (2) the growth story is decelerating once the Paycor bump washes out, capping any exponential upside; and (3) there is no expert conviction in the Synthos KB and the Street itself is a Hold. Our base fair value (~$108) is essentially at the market and at consensus — no edge, no urgency.
- Sizing: if owned at all, treat as an income/defensive satellite, ~1–3%, held primarily for the yield and low beta — not as a growth or conviction position. Better entries would come nearer the low-$90s (toward the rising 50-DMA), where the yield is fatter and the risk/reward improves.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, and immediately upgrade the conviction line if genuine expert coverage enters the KB. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $106.35.
- Single biggest risk: secular erosion of the SMB payroll moat by cheaper AI/self-serve competitors, compounded by SMB cyclicality.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage exists for PAYX in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no
claim_ids are cited because none exist, and none were fabricated (claim-ID reconciliation makes fabricated conviction structurally impossible). - Data as-of: fundamentals 2026-05-31 (FY26 / Q4'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Segmentation caveat: product segments predate full Paycor consolidation; FMP provides no geographic segmentation. Peer set is a broad Industrials cohort, not payroll/HCM pure-plays (ADP, the direct rival, is absent).
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").